Epigenomics Joins Forces with hundreds of Organizations to Increase Colorectal Cancer Screening Rates in the United States “80% by 2018” is a shared goal to have […]

Asterand Bioscience and MolecularMD announce a partnership to accelerate targeted therapeutic biomarker validation, optimization, development and commercialization  — PORTLAND, OR and CAMBRIDGE, MA and DETROIT, MI–( […]

Curetis’ Global Installed Base Expanding to Over 150 Unyvero Analyzers – Completion of EMEA Direct Sales team build-out drives 46% growth in system installations over the […]

Journal of “Cancer Treatment and Research Communications” Publishes Results of Study with Blood Test Epi proColon® ADMIT Study Results Demonstrate Higher Uptake of a Colorectal Cancer […]

ARUP Laboratories to Offer Epi proColon®, Epigenomics’ Blood-Based Colorectal Cancer Screening Test (Press Release) Berlin (Germany) and Germantown, MD (U.S.A.), November 8, 2016 – Epigenomics AG […]

USPSTF Guidelines May Have Used Old Data on Epigenomics Colorectal Cancer Screening Test Oct 26, 2016 NEW YORK (GenomeWeb) – The US Preventive Services Task Force […]

New Legislation Would Require CMS Coverage for Blood-Based Colorectal Cancer Screens Sep 29, 2016 | GenomeWeb [Original Article] NEW YORK – A bipartisan group of Congressional […]